

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
DX0935KSERIAL NO.:  
09/521,335INFORMATION DISCLOSURE STATEMENT  
FOR PATENTAPPLICANT:  
Oppmann *et al.*FILING DATE:  
March 9, 2000GROUP:  
1643 1647

SEP 06 2000 (Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
RCW	AA 5,457,038	10/95	Trinchieri <i>et al</i>			
↓	AB 5,741,772	4/98	Chang			
	AC					

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AD WO 98/33922					
	AE WO 99/00415					
RCW	AF WO 98/11225	3/98	wipo			
↓	AG WO 98/31811	7/98	↓			
	AH WO 98/49307	11/98	↓			
	AI EP 0 759 466	2/97	EPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	DeChiara <i>et al.</i> , "Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth", <i>Cell</i> , 83:313-322 (1995).
	AK	Elson <i>et al.</i> , "Definition: 'Homo sapiens cytokine-like factor-1 precursor (CLE-1) mRNA, complete cds'", <i>GenBank</i> , Accession Number AF059293 (1998).
	AL	Elson <i>et al.</i> , "Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family", <i>J Immunol</i> , 161:1371-1379 (1998).
	AM	Gately <i>et al.</i> , "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses", <i>Annu Rev Immunol</i> , 16:495-521 (1998).
	AN	Gough <i>et al.</i> , "Definition: 'Murine mRNA for leukaemia inhibitory factor (LIF)'", <i>GenBank</i> , Accession Number X06381 (1995).
	AO	Habecker <i>et al.</i> , "A sweat gland-derived differentiation activity acts through known cytokine signaling pathways", <i>J Biol Chem</i> , 272:30421-30428 (1997).
	AP	McDonald, "Definition: 'Human CNTF gene for ciliary neurotrophic factor'", <i>GenBank</i> , Accession Number X60542 (1991).
	AQ	Pennica <i>et al.</i> , "Definition: 'Mus musculus cardiotrophin-1 mRNA, complete cds'", <i>GenBank</i> , Accession Number U18366 (1995).
	AR	Pennica <i>et al.</i> , "Definition: 'Human cardiotrophin-1 (CTF1) mRNA, complete cds'", <i>GenBank</i> , Accession Number U43030 (1996).
	AS	Saotome <i>et al.</i> , "Definition: 'Mus musculus zinc finger protein (Pzf) mRNA, partial cds, and ciliary neurotrophic factor (Cntf) mRNA, complete cds'", <i>GenBank</i> , Accession Number U05342 (1995).
	AT	Shelton, "Are there more members of the CNTF-GPA family?", <i>Perspect Devel Neurobiol</i> , 4:101-107 (1996).
	AV	Stahl <i>et al.</i> , "Definition: 'Human leukemia inhibitory factor (LIF) gene, complete cds'", <i>GenBank</i> , Accession Number M63420, J05436 (1994).
	AW	Ware <i>et al.</i> , "Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death", <i>Development</i> , 121:1283-1299 (1995).
	AX	Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO: 2, as the query and citing Accession Numbers: 99P-W94466, 98P-W56141, 98P-W29715, 98P-W56142, 98P-W29716, 97P-W29237, 96P-R88204, 95P-R83965, Derwent Information Ltd., London.
	AY	Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO: 12, as the query and citing Accession Numbers: 98P-W59805, 98P-W55012, 98P-W55011, 98P-W59804, 98P-W55014, 98P-W55015, 98P-W55016, 92P-R26334, 97P-W17859, 96P-R94576, 92P-R24273, 92P-R22228, 91P-R10795; Derwent Information Ltd., London.
	AZ	Fischer <i>et al.</i> , "A bioactive designer cytokine for human hematopoietic progenitor cell expansion", <i>Nat Biotechnol</i> , 15:142-145 (1997).

EXAMINER

DATE CONSIDERED

P. Hayes

3/31/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTACHMENT NO.:  
DX0935KRECEIVED  
SEP 12 2000INFORMATION DISCLOSURE STATEMENT  
FOR PATENT

(Use several sheets if necessary)

APPLICANT:  
Oppmann *et al.*FILING DATE:  
March 9, 2000GROUP:  
1643 1647  
TECH CENTER: 1600/2900

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	BA					
	BB					
	BC					

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
RCN	BD	WO 95/11303	4/95	§ WIPO			
	BE	WO 99/20755	4/99	" "			
	BF	WO 99/28462	6/99	" "			
	BG	WO 99/35264	7/99	" "			
	BH	WO 99/40195	8/99	" "			
	BI						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RCN	BJ	Peters <i>et al.</i> , "In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6", <i>J Immunol</i> , 161:3575-3581 (1998).
	BK	Rakemann <i>et al.</i> , "The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro", <i>J Biol Chem</i> , 274:1257-1266 (1999).
	BL	Shi <i>et al.</i> , "Computational EST database analysis identifies a novel member of the neurotrophic cytokine family", <i>Biochem Biophys Res Commun</i> , 262:132-138 (1999).
	BM	Senaldi <i>et al.</i> , "Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family", <i>Proc Natl Acad Sci USA</i> , 96:11458-11463 (1999).
	BN	
	BO	
	BP	
	BQ	
	BR	
	BS	
	BT	
	BU	
	BV	
	BW	
	BX	
	BY	
	BZ	

EXAMINER

DATE CONSIDERED

3/31/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY